Progenics Pharma (PGNX) Tops Q4 EPS by 4c

Progenics Pharma (NASDAQ: PGNX) reported Q4 EPS of ($0.10), $0.04 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $5.1 million versus the consensus estimate of $2.25 million.

For earnings history and earnings-related data on Progenics Pharma (PGNX) click here.

You May Also Be Interested In

• Key things to know ahead of SK Hynix’s blockbuster US listing
• Donerail urges Beazer Homes board to engage with DFH's $32 offer
• Citi upgrades Knight-Swift and Saia to Buy after trucking stock pullback